Edition:
United States

Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

10.00USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$10.00
Open
$9.99
Day's High
$10.00
Day's Low
$9.98
Volume
96,814
Avg. Vol
138,976
52-wk High
$10.20
52-wk Low
$3.20

Chart for

About

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth... (more)

Overall

Beta: 3.89
Market Cap(Mil.): $505.60
Shares Outstanding(Mil.): 50.56
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Seattle Genetics Announces Expiration Of Hart-Scott-Rodino Waiting Period

* SEATTLE GENETICS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD

Feb 16 2018

BRIEF-Seattle Genetics Commences Tender Offer For Cascadian Therapeutics

* SEATTLE GENETICS COMMENCES TENDER OFFER FOR CASCADIAN THERAPEUTICS, INC.

Feb 08 2018

BRIEF-Seattle Genetics Says If Deal Terminated Under, Cascadian Therapeutics To Pay Fee Of $17 Million

* SEATTLE GENETICS SAYS IF DEAL TERMINATED UNDER CERTAIN CIRCUMSTANCES, CASCADIAN THERAPEUTICS MAY BE REQUIRED TO PAY CO FEE OF $17 MILLION - SEC FILING Source text: (http://bit.ly/2E2RNXK) Further company coverage:

Jan 31 2018

BRIEF-Seattle Genetics To Acquire Cascadian Therapeutics

* SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE

Jan 31 2018

BRIEF-Cascadian Therapeutics Receives Pediatric Investigation Plan Waiver From The European Medicines Agency

* CASCADIAN THERAPEUTICS RECEIVES PEDIATRIC INVESTIGATION PLAN WAIVER FROM THE EUROPEAN MEDICINES AGENCY Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Jan 02 2018

BRIEF-Cascadian Therapeutics reports Q3 loss per share $0.28

* Cascadian Therapeutics reports third quarter 2017 financial results

Nov 08 2017

BRIEF-Cascadian Therapeutics announces FDA orphan drug designation granted to Tucatinib for the treatment of HER2 colorectal cancer

* Cascadian Therapeutics announces FDA orphan drug designation granted to tucatinib for the treatment of HER2+ metastatic colorectal cancer Source text for Eikon: Further company coverage:

Sep 27 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00
Eli Lilly and Co (LLY.N) $78.75 +1.56
Transgene SA (TRNG.PA) €3.04 -0.01
Puma Biotechnology Inc (PBYI.OQ) $68.25 +2.10

Earnings vs. Estimates